Table 3.
Description of the selected studies.
| Author Name, Country—Year of Publication | Type of Study | Sample Size | Age of BC Patients | Stage | Treatment | Time of Assessment | Questionnaires |
|---|---|---|---|---|---|---|---|
| Mean (SD) | % | % | |||||
| Ahmad A [21], Saudi Arabia—2017 | Cross-sectional | 145 | 50.3 (13.5) | I and II: 61.2 III and IV: 38.8 |
Cancer surgery: 64.8 Chemotherapy: 73.1 Radiotherapy: 57.9 Immunotherapy: 49 |
First year after cancer % Yes: 52.4 No: 47.6 |
SF-36 |
| Ahrafizadeh H [22], Iran—2017 | Cross-sectional | 100 | 46.8 (11.5) | - | Mastectomy: 58 Breast conservative surgery: 31 Chemotherapy: 100 |
During chemotherapy | WHOQOL-BREF |
| Akel R [23], Lebanon—2017 | Cross-sectional | 150 (121 Lebanese, 26 Iraqi, 6 other) | 53.5 (10.4) | I: 29.3 II: 38.7 III: 23.3 IV: 8.7 |
Chemotherapy: 79.3 Radiotherapy: 80.7 Surgery: 97.3 Hormone therapy: 86 |
0.5 to ≤ 2 years: 13.3 3 to ≤ 5 years: 68.7 ≥ 5 years: 18 |
FACT-B |
| Akin S [24], Turkey—2008 | Longitudinal | 141 | 46.9 (10.1) | I: 6.4 II: 47.5 III: 31.2 IV: 14.29 |
Chemotherapy: 100 Surgery: 76.6 |
Pre and Post chemotherapy | FACT-B |
| Alawadi S [25], Kuwait—2009 | Cross-sectional | 348 | 48.3 (10.3) | I: 7 II: 34.3 III: 36 IV: 22.7 |
Chemotherapy: 98.3 Radiotherapy: 21 Surgery: 58.6 |
During chemotherapy | EORTC-QLQ-C30 plus QLQ-BR23 |
| Albabtain H [26], Saudi Arabia—2018 | Cross-sectional | 95 | 25–39 years: 26.3 40–59 years: 47.4 > 60 years: 26.3 |
- | 89.5 undergoing cancer treatment | During cancer treatment | EORTC-QLQ-C30 plus QLQ-BR23 |
| Almutairi K [27], Saudi Arabia—2016 | Cross-sectional | 145 | 26–35 years: 13.1 36–45 years: 30.3 |
I: 21.4 II: 57.9 III and IV: 20 Distant metastasis: 0.7 |
Chemotherapy: 3.4 Radiotherapy: 2.1 Surgery: 31.7 Hormone therapy: 0.7 Combination modalities: 62.1 |
During the visit of outpatient clinics | EORTC-QLQ-C30 plus QLQ-BR23 |
| >46 years: 56.6 | |||||||
| Al-Naggar R [28], Yemen—2011 | Cross-sectional | 106 | < 55 years: 67.9 | III: 35.8 | Chemotherapy: 94.3 Radiotherapy: 63.2 Surgery: 85.8 |
unspecified | FACT-B |
| Al-Natour A [29], Jordan—2017 | Cross-sectional | 150 | 47.9 (9.7) | I: 25.5 II: 48.9 III: 19 IV: 6.6 |
- | During cancer treatment | FACT-G |
| Bagheri M [30], Iran—2015 | Case- Control | 50 cases 50 Healthy control |
Cases: 32 (0.5) Controls: 33.7 (4.2) |
- | - | unspecified | SF-36 |
| Bayram Z [31], Turkey—2014 | Cross-sectional | 105 | 50.1 (11.8) | I: 40 II: 37.1 III: 19.0 IV: 3.8 |
Chemotherapy: 100 |
Newly diagnosed and undergoing chemotherapy | FACT-G |
| Filazoglu G [32], Turkey—2008 | Cross-sectional | 188 | 45.1 (5.6) | I: 23.4 II: 55.9 III: 18.6 IV: 2.1 |
Chemotherapy: 17.6 Radiotherapy: 38.8 Chemotherapy + Radiotherapy: 14.4 No treatment: 29.3 Surgery: 100 |
After breast surgery for a minimum of 3 months before the study. | SF-36 |
| Hujeir H [33], Lebanon—2012 | Cross-sectional | 89 | 49.2 (11.1) | Metastasis: 37.1 | Chemotherapy: 47.2 Radiotherapy: 31.4 Surgery: 70.7 Hormone therapy: 15.7 |
30.6 (39.06) months |
EORTC-QLQ-C30 |
| Jafari N [34], Iran—2013 | Cross-sectional | 68 | 48 (10.3) | - | Radiotherapy: 100 | During Radiotherapy | EORTC-QLQ-C30 plus QLQ-BR23 |
| Jassim G [35], Bahrain—2013 | Cross-sectional | 239 | 50.2 (11.1) | I: 29.9 II: 44.8 III and IV: 25.3 |
Chemotherapy: 80.5 Radiotherapy: 83.9 Lumpectomy: 51.3 Mastectomy: 50 Lymph node dissection: 85.1 Hormone therapy: 69.8 |
Early diagnosed: 14.6 Transitional period: 53.6 Long-term survivors: 31.8 |
EORTC-QLQ-C30 plus QLQ-BR23 |
| Khalili N [36], Iran—2013 | Cross-sectional | 62 | 45.8 (6.7) | IA: 1.6 IB: 6.4 IIA: 22.5 IIB: 25.8 IIIA: 16.1 IIIB: 14.5 IIIC: 8.1 |
- | Diagnosis with BC in a recent year | EORTC-QLQ-C30 |
| Kiadaliri A [37], Iran—2012 | Longitudinal | 100 | TAC: 46.7 (8.2) FAC: 49.3 (11.5) |
- | - | Before and after chemotherapy and 4 months later | EORTC-QLQ-C30 |
| Mohammadi S [38], Iran—2013 | Cross-sectional | 100 | 47.8(6.7) | I: 8 II: 41 III: 51.3 |
All patients completed 3 phases of BC treatment, which included mastectomy, chemotherapy, radiation therapy. | Duration of survivorship: 2 years: 25 3 years: 44 4 years: 25 5 years: 6 |
EORTC-QLQ-C30 |
| Moradi R [39], Iran—2017 | Cross-sectional | 87 | 48.25 (11.9) | - | Chemotherapy: 100 | After chemotherapy | WHOQOL-BREF |
| Musarezaei A [40], Iran—2015 | Cross-sectional | 105 | 45.3 (4.6) | II: 50 | Mastectomy: 100 | Underwent mastectomy (at least 1 year and a maximum of 5 years previously) | NMCBRI-Q |
| Najafi F [41], Iran—2016 | Cross-sectional | 148 | 47.6 (10.1) | In situ: 7.1 Local: 45.7 Loco/regional: 40 Advanced: 7.1 |
Patients completed at least 2 chemotherapy sessions (only those with very small tumors did not undergo chemotherapy). | Time since diagnosis: 17.2 (1.4) months |
EORTC-QLQ-C30 |
| Nikamenesh Z [42], Iran—2017 | Cross-sectional | 42 | 30-50 years: 69% | - | - | Diagnosis for at least 6 months and under treatment | EORTC-QLQ-C30 |
| Pehlivan S [43], Turkey—2016 | Cross-sectional | 61 | 50.37 (11.8) | I: 9.8 II: 59 III: 23 IV: 8.2 |
Chemotherapy: 19.7 Chemotherapy + Radiotherapy: 80.3 |
During Radiotherapy | EORTC QLQ-BR23 |
| Rohani C [44], Iran—2015 | Case-control | Cases (BC patients): 162 Controls: 210 |
Cases: 46.1 (9.8) Control: 46.6 (8.4) |
0: 2.5 I: 22.8 II:49.4 III: 24.1 IV: 1.2 |
Chemotherapy: 79 Radiotherapy: 75.3 Hormone therapy: 68.5 |
Baseline pre-diagnosis phase of BC (T1) and 6 months post pre-diagnosis (T2). | EORTC-QLQ-C30 |
| Safa A [45], Iran—2014 | Cross-sectional | 92 | 42.9 (8.7) | - | - | At least 3 months since treatment | QOL-BC |
| Shakeri J [46], Iran—2016 | Cross-sectional | 98 | 47.6 (14) | - | - | Unspecified | LQI |
| Saatci E [47], Turkey—2007 | Cross-sectional | 100 | 48.64 (10.6) | I: 49 II: 51 |
Chemotherapy: 59 Radiotherapy: 10 Chemotherapy + Radiotherapy: 31 |
22.6 (24.3) months | FACT-G |
| Safaee A [48], Iran—2008 | Cross-sectional | 119 | 48.27 (11.4) | Well differentiated: 33.6 Moderately differentiated: 42 Poorly differentiated: 24.4 |
Chemotherapy: 100 | Time since diagnosis: < 4 months: 39.5 4-12 months: 34.4 >12 months: 26.1 |
EORTC-QLQ-C30 |
| Shandiz,F H [49], Iran—2008 | Cross-sectional | 94 | 45.20(8.6) | - | Chemotherapy: 100 Radiotherapy: 69.1 Surgery: 100 Hormone therapy: 52.1 |
During chemotherapy | EORTC-QLQ-C30 |
| Sinaei F [50], Iran—2017 | Case-control | Mastectomy group: 45 Reconstruction group: 61 |
Mastectomy: 50.2 (8.5) Reconstruction: 46.7 (8.1) |
- | Surgery: 100 Chemo radiation: Mastectomy: 86.7 Reconstruction: 90 |
unspecified | EORTC-QLQ-C30 plus QLQ-BR23 |
| Uzun Ö [51], Turkey—2004 | Cross-sectional | 72 | 50.1 (9.3) | I: 24 II: 58.3 III: 16.7 |
Chemotherapy: 100 Radiotherapy: 52.8 Surgery: 100 |
unspecified | QoLS |
| Zamanian H [52], Iran—2015 | Cross-sectional | 224 | 47.1 (9.0) | - | Chemotherapy: 61.6 Radiotherapy: 40 Surgery: 26.8 |
Time since diagnosis: 43.8 (37.6) months | FACT-B |
| Zargani A [53], Iran—2018 | Cross-sectional | 84 | 54.7 (10.4) | - | All patients undergoing cancer treatment (surgery, radiotherapy or chemotherapy). | Diagnosis at least 1 year prior | SF-36 |
Age of breast cancer patients and time since diagnosis of BC are presented as mean (standard deviation), stage of BC I, II, III, and IV, and interventions (chemotherapy, radiotherapy, surgery, and hormonotherapy) are presented as number (percentage). Abbreviations: BR23: Breast cancer specific module. EORTC-QLQ-C30: European Organization for Research and treatment of Cancer—Quality of Life Questionnaire. FACT-B: The Functional Assessment of Cancer Therapy—Breast Cancer. FACT-G: The Functional Assessment of Cancer Therapy—General Questionnaire. LQI: Life quality inventory. NMCBRI-Q: The national medical center and Beckman research institute questionnaire. QoLS: The Quality of Life Scale. SF-36: Short-Form Health Survey Questionnaire. WHOQOL-BREF: WHO questionnaire of quality of life. FAC: fluorouracil, doxorubicin, and cyclophosphamide. TAC: docetaxel, doxorubicin, and cyclophosphamide.